Discovery - University of Dundee - Online Publications

Library & Learning Centre

Pyrosequencing-based methods reveal marked inter-individual differences in oncogene mutation burden in human colorectal tumours

Standard

Pyrosequencing-based methods reveal marked inter-individual differences in oncogene mutation burden in human colorectal tumours. / Weidlich, S.; Walsh, K.; Crowther, D.; Burczynski, M. E.; Feuerstein, G.; Carey, Francis; Steele, R. J. C.; Wolf, C. R.; Miele, G. (Lead / Corresponding author); Smith, G. (Lead / Corresponding author).

In: British Journal of Cancer, Vol. 105, No. 2, 12.07.2011, p. 246-254.

Research output: Contribution to journalArticle

Harvard

Weidlich, S, Walsh, K, Crowther, D, Burczynski, ME, Feuerstein, G, Carey, F, Steele, RJC, Wolf, CR, Miele, G & Smith, G 2011, 'Pyrosequencing-based methods reveal marked inter-individual differences in oncogene mutation burden in human colorectal tumours' British Journal of Cancer, vol 105, no. 2, pp. 246-254., 10.1038/bjc.2011.197

APA

Weidlich, S., Walsh, K., Crowther, D., Burczynski, M. E., Feuerstein, G., Carey, F., ... Smith, G. (2011). Pyrosequencing-based methods reveal marked inter-individual differences in oncogene mutation burden in human colorectal tumours. British Journal of Cancer, 105(2), 246-254. 10.1038/bjc.2011.197

Vancouver

Weidlich S, Walsh K, Crowther D, Burczynski ME, Feuerstein G, Carey F et al. Pyrosequencing-based methods reveal marked inter-individual differences in oncogene mutation burden in human colorectal tumours. British Journal of Cancer. 2011 Jul 12;105(2):246-254. Available from: 10.1038/bjc.2011.197

Author

Weidlich, S.; Walsh, K.; Crowther, D.; Burczynski, M. E.; Feuerstein, G.; Carey, Francis; Steele, R. J. C.; Wolf, C. R.; Miele, G. (Lead / Corresponding author); Smith, G. (Lead / Corresponding author) / Pyrosequencing-based methods reveal marked inter-individual differences in oncogene mutation burden in human colorectal tumours.

In: British Journal of Cancer, Vol. 105, No. 2, 12.07.2011, p. 246-254.

Research output: Contribution to journalArticle

Bibtex - Download

@article{c0e6086c4482473384ef1c606196fd02,
title = "Pyrosequencing-based methods reveal marked inter-individual differences in oncogene mutation burden in human colorectal tumours",
keywords = "K-Ras, Mutation, Dideoxy sequencing, Pyrosequencing, Colorectal tumour, Personalised medicine, Growth factor receptor, Kirsten Ras mutations, PIK3CA mutations, Prognostic significance, Gene mutation, Colon cancer, CETUXIMAB, BRAF",
author = "S. Weidlich and K. Walsh and D. Crowther and Burczynski, {M. E.} and G. Feuerstein and Francis Carey and Steele, {R. J. C.} and Wolf, {C. R.} and G. Miele and G. Smith",
year = "2011",
doi = "10.1038/bjc.2011.197",
volume = "105",
number = "2",
pages = "246--254",
journal = "British Journal of Cancer",
issn = "0007-0920",

}

RIS (suitable for import to EndNote) - Download

TY - JOUR

T1 - Pyrosequencing-based methods reveal marked inter-individual differences in oncogene mutation burden in human colorectal tumours

A1 - Weidlich,S.

A1 - Walsh,K.

A1 - Crowther,D.

A1 - Burczynski,M. E.

A1 - Feuerstein,G.

A1 - Carey,Francis

A1 - Steele,R. J. C.

A1 - Wolf,C. R.

A1 - Miele,G.

A1 - Smith,G.

AU - Weidlich,S.

AU - Walsh,K.

AU - Crowther,D.

AU - Burczynski,M. E.

AU - Feuerstein,G.

AU - Carey,Francis

AU - Steele,R. J. C.

AU - Wolf,C. R.

AU - Miele,G.

AU - Smith,G.

PY - 2011/7/12

Y1 - 2011/7/12

N2 - <p>BACKGROUND: The epidermal growth factor receptor-targeted monoclonal antibody cetuximab (Erbitux) was recently introduced for the treatment of metastatic colorectal cancer. Treatment response is dependent on Kirsten-Ras (K-Ras) mutation status, in which the majority of patients with tumour-specific K-Ras mutations fail to respond to treatment. Mutations in the oncogenes B-Raf and PIK3CA (phosphoinositide-3-kinase) may also influence cetuximab response, highlighting the need for a sensitive, accurate and quantitative assessment of tumour mutation burden.</p><p>METHODS: Mutations in K-Ras, B-Raf and PIK3CA were identified by both dideoxy and quantitative pyrosequencing-based methods in a cohort of unselected colorectal tumours (n = 102), and pyrosequencing-based mutation calls correlated with various clinicopathological parameters.</p><p>RESULTS: The use of quantitative pyrosequencing-based methods allowed us to report a 13.7% increase in mutation burden, and to identify low-frequency (&lt;30% mutation burden) mutations not routinely detected by dideoxy sequencing. K-Ras and B-Raf mutations were mutually exclusive and independently associated with a more advanced tumour phenotype.</p><p>CONCLUSION: Pyrosequencing-based methods facilitate the identification of low-frequency tumour mutations and allow more accurate assessment of tumour mutation burden. Quantitative assessment of mutation burden may permit a more detailed evaluation of the role of specific tumour mutations in the pathogenesis and progression of colorectal cancer and may improve future patient selection for targeted drug therapies. British Journal of Cancer (2011) 105, 246-254. doi: 10.1038/bjc.2011.197 www.bjcancer.com Published online 28 June 2011 (C) 2011 Cancer Research UK</p>

AB - <p>BACKGROUND: The epidermal growth factor receptor-targeted monoclonal antibody cetuximab (Erbitux) was recently introduced for the treatment of metastatic colorectal cancer. Treatment response is dependent on Kirsten-Ras (K-Ras) mutation status, in which the majority of patients with tumour-specific K-Ras mutations fail to respond to treatment. Mutations in the oncogenes B-Raf and PIK3CA (phosphoinositide-3-kinase) may also influence cetuximab response, highlighting the need for a sensitive, accurate and quantitative assessment of tumour mutation burden.</p><p>METHODS: Mutations in K-Ras, B-Raf and PIK3CA were identified by both dideoxy and quantitative pyrosequencing-based methods in a cohort of unselected colorectal tumours (n = 102), and pyrosequencing-based mutation calls correlated with various clinicopathological parameters.</p><p>RESULTS: The use of quantitative pyrosequencing-based methods allowed us to report a 13.7% increase in mutation burden, and to identify low-frequency (&lt;30% mutation burden) mutations not routinely detected by dideoxy sequencing. K-Ras and B-Raf mutations were mutually exclusive and independently associated with a more advanced tumour phenotype.</p><p>CONCLUSION: Pyrosequencing-based methods facilitate the identification of low-frequency tumour mutations and allow more accurate assessment of tumour mutation burden. Quantitative assessment of mutation burden may permit a more detailed evaluation of the role of specific tumour mutations in the pathogenesis and progression of colorectal cancer and may improve future patient selection for targeted drug therapies. British Journal of Cancer (2011) 105, 246-254. doi: 10.1038/bjc.2011.197 www.bjcancer.com Published online 28 June 2011 (C) 2011 Cancer Research UK</p>

KW - K-Ras

KW - Mutation

KW - Dideoxy sequencing

KW - Pyrosequencing

KW - Colorectal tumour

KW - Personalised medicine

KW - Growth factor receptor

KW - Kirsten Ras mutations

KW - PIK3CA mutations

KW - Prognostic significance

KW - Gene mutation

KW - Colon cancer

KW - CETUXIMAB

KW - BRAF

UR - http://www.scopus.com/inward/record.url?scp=79960231716&partnerID=8YFLogxK

U2 - 10.1038/bjc.2011.197

DO - 10.1038/bjc.2011.197

M1 - Article

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 2

VL - 105

SP - 246

EP - 254

ER -

Documents

Library & Learning Centre

Contact | Accessibility | Policy